search
Back to results

Mechanisms of Prediabetic States in Sleep Apnea

Primary Purpose

Sleep Apnea, Pre-diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Continuous positive airway pressure
Niacin
Sponsored by
University of Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Sleep Apnea focused on measuring Sleep

Eligibility Criteria

20 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Overweight or obese
  • Prediabetic
  • Sleep apnea

Exclusion Criteria:

  • Diabetic
  • Severe hypertension
  • Taking medications that can confound assessments
  • Any history of known bleeding disorders
  • Any underlying disease likely to limit life span or increase risk of intervention
  • Currently pregnant, trying to get pregnant or nursing

Sites / Locations

  • University of ChicagoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Active Comparator

Active Comparator

Arm Label

Untreated

Continuous positive airway pressure (CPAP) treatment

Niacin

Arm Description

Untreated condition (obstructive sleep apnea)

Continuous positive airway pressure (CPAP) treatment

Untreated, pharmacological suppression of lipolysis by Niacin

Outcomes

Primary Outcome Measures

Plasma norepinephrine levels
Plasma norepinephrine will be measured in blood
Plasma norepinephrine levels
Plasma norepinephrine will be measured in blood
Plasma norepinephrine levels
Plasma norepinephrine will be measured in blood

Secondary Outcome Measures

Full Information

First Posted
December 18, 2019
Last Updated
March 16, 2023
Sponsor
University of Chicago
Collaborators
Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI), AdventHealth
search

1. Study Identification

Unique Protocol Identification Number
NCT04234217
Brief Title
Mechanisms of Prediabetic States in Sleep Apnea
Official Title
Mechanisms of Prediabetic States in Sleep Apnea
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 26, 2019 (Actual)
Primary Completion Date
July 15, 2025 (Anticipated)
Study Completion Date
July 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Chicago
Collaborators
Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI), AdventHealth

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to better understand how sleep apnea contributes to the development of diabetes.
Detailed Description
Substantial evidence indicates that obstructive sleep apnea (OSA) is associated with impaired glucose metabolism, however, metabolic mechanisms underlying this association remain unclear. This mechanistic study will determine systemic and cellular metabolic pathways that contribute to impaired glucose metabolism in obstructive sleep apnea (OSA). Understanding of how obstructive sleep apnea (OSA) affects glucose metabolism may help identify novel targets for risk prediction and/or treatment of metabolic impairments beyond continuous positive airway pressure (CPAP). Obstructive sleep apnea (OSA) patients with prediabetes will be studied under three in-laboratory conditions in a randomized cross-over design: untreated condition (obstructive sleep apnea), treated condition (continuous positive airway pressure), untreated but pharmacologically suppressed lipolysis condition (Niacin). The investigator will perform whole body and cellular assessments under each study condition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Pre-diabetes
Keywords
Sleep

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Untreated
Arm Type
No Intervention
Arm Description
Untreated condition (obstructive sleep apnea)
Arm Title
Continuous positive airway pressure (CPAP) treatment
Arm Type
Active Comparator
Arm Description
Continuous positive airway pressure (CPAP) treatment
Arm Title
Niacin
Arm Type
Active Comparator
Arm Description
Untreated, pharmacological suppression of lipolysis by Niacin
Intervention Type
Device
Intervention Name(s)
Continuous positive airway pressure
Other Intervention Name(s)
CPAP
Intervention Description
Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
Intervention Type
Other
Intervention Name(s)
Niacin
Other Intervention Name(s)
Suppression of lipolysis by niacin infusion
Intervention Description
Suppression of lipolysis by niacin infusion
Primary Outcome Measure Information:
Title
Plasma norepinephrine levels
Description
Plasma norepinephrine will be measured in blood
Time Frame
Untreated, within 4 months of screening
Title
Plasma norepinephrine levels
Description
Plasma norepinephrine will be measured in blood
Time Frame
CPAP, within 4 months of screening
Title
Plasma norepinephrine levels
Description
Plasma norepinephrine will be measured in blood
Time Frame
Niacin, within 4 months of screening

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Overweight or obese Prediabetic Sleep apnea Exclusion Criteria: Diabetic Severe hypertension Taking medications that can confound assessments Any history of known bleeding disorders Any underlying disease likely to limit life span or increase risk of intervention Currently pregnant, trying to get pregnant or nursing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Becky Tucker, BA
Phone
773-702-2348
Email
sleepstudy@uchicago.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Esra Tasali, MD
Organizational Affiliation
University of Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Esra Tasali, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Mechanisms of Prediabetic States in Sleep Apnea

We'll reach out to this number within 24 hrs